BSE · 536565
Novelix Pharmaceuticals Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹37 Cr with net profit ₹1 Cr — a 3.2% net margin, versus 3.61% the period before.
Shareholding
As of 2026-09-30
- Promoter54.29%
- Public45.71%
3,192 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.94× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Trading · ranked #163 of 689 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Adani Enterprises Limited | ₹3,35,624 Cr | 130.38 | 3.54 | 3.93% | 6.78% |
| Avenue Supermarts Limited | ₹2,04,427 Cr | 65.59 | 7.83 | 11.94% | 4.2% |
| Trent Ltd. | ₹1,55,379 Cr | 84.98 | 22.25 | 24.62% | 8.64% |
| FSN E-Commerce Ventures Ltd. | ₹98,116 Cr | 368.28 | 68.24 | 13.87% | 2.41% |
| Aditya Infotech Limited | ₹48,793 Cr | 102.24 | 14.45 | 19.61% | 9.77% |
| Aegis Logistics Limited | ₹41,520 Cr | 31.16 | 6.24 | 20.01% | 14.99% |
| Vishal Mega Mart Limited | ₹41,203 Cr | 45.81 | 5.22 | 11.37% | 6.45% |
| Premier Energies Limited | ₹38,368 Cr | 23.04 | 8.91 | 35.05% | 19.67% |
| Redington Limited | ₹27,472 Cr | 15.27 | 2.7 | 14.67% | 1.33% |
| Honasa Consumer Limited | ₹14,707 Cr | 58.28 | 10.41 | 14.16% | 9.75% |
| Novelix Pharmaceuticals Limited(this company) | ₹175 Cr | 48.35 | 2.66 | 5.5% | 2.46% |
AI analysis
AI-generated · google/gemini-2.5-flashNovelix Pharmaceuticals Limited (536565) has a market capitalization of Rs 101 Cr. The company reported a negative return on equity (ROE) of -30.18% and a negative return on capital employed (ROCE) of -32.45%. Debt-to-equity is low at 0.01.
Positives
- +The debt-to-equity ratio is low at 0.01.
- +Promoter holding is 54.29% as of July 31, 2026.
- +No shares are pledged by the promoters.
Negatives
- −The company has a negative profit margin of -49.32%.
- −Return on equity (ROE) is negative at -30.18%.
- −Return on capital employed (ROCE) is negative at -32.45%.
- −The company's EPS is 0, indicating no earnings per share.
- −Quarterly results have not been disclosed since September 2022.
Financial Performance
The company’s annual revenue for March 2026 was Rs 25.19 Cr. For the quarter ending September 2022, revenue was Rs 1.24 Cr, with a net profit of -0.13 Cr. However, recent annual data shows increasing revenue over the past periods, reaching Rs 48.4 Cr in December 2025 before declining to Rs 25.19 Cr in March 2026.
Profitability & Returns
Novelix Pharmaceuticals Limited has a negative profit margin of -49.32%. The return on equity (ROE) stands at -30.18%, and the return on capital employed (ROCE) is -32.45%. These figures indicate that the company is currently not generating positive returns for its shareholders or from its capital employed.
Balance Sheet
The company has a low debt-to-equity ratio of 0.01, suggesting minimal reliance on debt financing. The book value per share is Rs 12.51. There is no information available regarding the company's dividend yield, which currently stands at 0%.
Ownership & Pledges
Promoter holding in Novelix Pharmaceuticals Limited is 54.29% as of July 31, 2026. Public shareholding is 45.71%. There are currently no shares pledged by the promoters. The number of shareholders is 3127.
Regulatory & Surveillance
The company is currently under ESM (Enhanced Surveillance Measure) Stage 1, which typically involves additional monitoring by the exchange to ensure market integrity and protect investor interests.
Data as of — price: 2026-10-28 · financials: Jun 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Novelix Pharmaceuticals Limitedshare price & fundamentals